Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
about
Circumventing antivector immunity: potential use of nonhuman adenoviral vectorsPre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responsesHIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.The influence of innate and pre-existing immunity on adenovirus therapyIdentification of sites in adenovirus hexon for foreign peptide incorporation.A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector.Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infectionSubstitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice.Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.Current progress in the development of a prophylactic vaccine for HIV-1.Using multivalent adenoviral vectors for HIV vaccinationUtilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 HexonSeroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccinesIdentification and Application of Neutralizing Epitopes of Human Adenovirus Type 55 Hexon Protein.Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectorsGene transfer of active Akt1 by an infectivity-enhanced adenovirus impacts β-cell survival and proliferation differentially in vitro and in vivoOptimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach.Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3.Pdx1 and controlled culture conditions induced differentiation of human amniotic fluid-derived stem cells to insulin-producing clusters.Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.Postentry neutralization of adenovirus type 5 by an antihexon antibody.Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.Improving adenovirus based gene transfer: strategies to accomplish immune evasion.Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies.A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.Rescue of chimeric adenoviral vectors to expand the serotype repertoire.Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model.Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized Mice.Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.Antigenic variability among two subtypes of human adenovirus serotype 7.Structure-based identification of a major neutralizing site in an adenovirus hexon.Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner.
P2860
Q26995655-BE43E405-E78E-4C5C-B39F-5EDBFFD4894AQ27304910-F0C62F30-CB0F-4D64-8206-BA779657172AQ33646773-2F12FA6A-846D-47A2-B510-C0B8B623B0D3Q33655401-364AF2A5-A00C-4589-BF92-57EADA25E6EBQ33737591-6F34E982-B62A-4797-A1D0-EC3E22C62105Q33786140-0F919C11-C534-49CA-901F-6B164169B8A4Q33940167-7E571D93-9FA1-4CB3-809B-347F393DC945Q34075166-42E80852-9951-4B82-AFEF-502B7C254DB9Q34153846-95EBB9B2-891F-47CB-BD86-CC7CFCE16C92Q34162092-3964CC7A-B00B-4FC2-9266-C5542BBEF5BDQ34358402-A1D19AC0-107F-4E23-A423-58BA6C5B0D45Q34502108-147CD0F1-51F1-4727-A81A-4765966BFB13Q34653777-4E06FFB5-B7AB-495E-9C26-D68065DC0B14Q35973091-AE5C54FD-7F7C-4195-BE66-C924D3121817Q36058021-42ADCC94-3CD5-490A-AB34-4E4F33448422Q36097089-DD7C458E-BF5D-42F1-8A65-C80D491DDC4CQ36246676-CAF13038-FD2C-439E-8C4E-6F772B90E0F2Q36625165-D0CAE559-7859-4C08-BDEB-C83B6F84D801Q36645405-EF8F4C56-C733-4BA8-92AB-B343E79AE976Q36707352-1A2180A3-B4A5-498C-AAD0-A617E7794FC0Q36873456-5B72A4B6-4ADA-4161-9F69-E0FBE83CB23CQ36966327-B5B2A633-73CE-493D-A0C0-BA3332FD9A1FQ37404870-DC002F72-D490-4DE3-9D93-AC7ABF9FFB5CQ37417604-5A49A7E1-364A-47ED-986A-CBDD6CF36BAEQ37490265-F1D69A53-D2B5-4420-A0F5-9E897E96EDDCQ37596703-B52FF93F-29C3-4604-96D8-72134BDDC3D9Q37603360-D4BA97D9-5043-45BB-9979-64151AAF9A34Q37945219-DD8FC24B-EE94-4E78-8CA9-1DE92895DB0EQ38008337-1CFE21D9-1C2B-4002-977B-D497B28ED393Q38614156-2086E046-8174-4059-9CF7-B59465AA71E8Q38618197-EA6CEC43-FB64-45EA-BABE-6F605C801B78Q39441716-B16B627D-8DD1-4495-A37A-2707A6DA192CQ40063020-C00D451B-426E-46FE-8D8D-8E2C11521823Q40188439-168094A6-FB89-4EFB-886E-711A89820311Q40196760-CA8BAD8B-9CF9-4A93-B654-D63BB19031BDQ41249890-31077298-27A9-4ED3-992F-EEAA690348E7Q42064105-A59A1DED-6F02-43D8-8F02-3BB53E9EDDE2Q42222645-FF33BAB3-DEEC-4C82-88D8-7D703EDA5CC0Q42259707-72EE86A5-E5E2-4AAD-9C41-9CE88525DFAFQ43008071-4DB4E313-E797-4A7E-9696-C1A7D603B9B6
P2860
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@ast
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@en
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@nl
type
label
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@ast
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@en
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@nl
prefLabel
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@ast
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@en
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@nl
P2093
P2860
P1433
P1476
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.
@en
P2093
Elena Kashentseva
Igor Dmitriev
Minghui Wang
Toshiro Seki
P2860
P304
12775-12782
P356
10.1128/JVI.76.24.12775-12782.2002
P407
P577
2002-12-01T00:00:00Z